Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 8.9% – Here’s What Happened

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s stock price fell 8.9% during trading on Monday. The company traded as low as $3.07 and last traded at $3.07. 88,257 shares traded hands during trading, a decline of 25% from the average daily volume of 118,054 shares. The stock had previously closed at $3.37.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Armata Pharmaceuticals in a research note on Tuesday, September 22nd. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.00.

Armata Pharmaceuticals Stock Down 4.8%

The company’s 50 day moving average price is $4.41 and its 200 day moving average price is $6.55. The firm has a market capitalization of $113.21 million, a price-to-earnings ratio of -0.40 and a beta of 1.40.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.17. Armata Pharmaceuticals had a negative return on equity of 12.24% and a negative net margin of 3,467.04%. The firm had revenue of $2.51 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, analysts expect that Armata Pharmaceuticals, Inc. will post 0.50 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC purchased a new position in Armata Pharmaceuticals during the 3rd quarter worth approximately $50,000. Bank of America Corp DE acquired a new stake in Armata Pharmaceuticals during the 2nd quarter valued at approximately $73,000. Madison Asset Management LLC purchased a new stake in shares of Armata Pharmaceuticals in the 2nd quarter valued at $13,654,000. BlackRock Inc. purchased a new stake in shares of Armata Pharmaceuticals in the 2nd quarter valued at $3,629,000. Finally, Deutsche Bank AG purchased a new stake in shares of Armata Pharmaceuticals in the 2nd quarter valued at $78,000. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat bacterial infections, including infections caused by antibiotic-resistant pathogens. Bacteriophages, or “phages,” are viruses that selectively target and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company’s pipeline includes investigational phage therapies for serious respiratory and systemic infections.